Retreatment With Osimertinib Following Pneumonitis

Clin Lung Cancer. 2018 Jan;19(1):e53-e55. doi: 10.1016/j.cllc.2017.06.017. Epub 2017 Jul 6.
No abstract available

Keywords: Drug-related pneumonitis; EGFR; NSCLC; Re-challenge post pneumonitis; T790M inhibitor.

Publication types

  • Case Reports

MeSH terms

  • Acrylamides
  • Aged
  • Aged, 80 and over
  • Aniline Compounds
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / secondary
  • Carcinoma, Adenosquamous / drug therapy*
  • Carcinoma, Adenosquamous / secondary
  • Disease Progression
  • ErbB Receptors / genetics
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / secondary
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged
  • Mutation / genetics*
  • Piperazines / therapeutic use*
  • Pneumonia / drug therapy*
  • Protein Kinase Inhibitors / therapeutic use*
  • Steroids / therapeutic use

Substances

  • Acrylamides
  • Aniline Compounds
  • Piperazines
  • Protein Kinase Inhibitors
  • Steroids
  • osimertinib
  • EGFR protein, human
  • ErbB Receptors